G protein‐coupled receptors can control the Hippo/YAP pathway through Gq signaling

Zindel, Diana; Mensat, Patrick; Vol, Claire; Homayed, Zeinab; Charrier‐Savournin, Fabienne; Trinquet, Eric; Banères, Jean-Louis; Pin, Jean‐Philippe; Pannequin, Julie; Roux, Thomas; Dupuis, Elodie; Prézeau, Laurent

doi:10.1096/fj.202002159r

Cited by 19 publications

(13 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…115 The Hippo pathway has been shown to be regulated by GPCR signalling. [116][117][118][119] For example, it was shown that GPCR ligands such as thrombin or lysophosphatidic acid (LPA) could activate YAP in fibroblasts and sensitize them to TGF-β1. 120 Additionally, sphingosine-1-phosphate (SIP) is a ligand of GPCR.…”

Section: Key Components Of the Hippo Pathwaymentioning

confidence: 99%

The Hippo signalling pathway and its implications in human health and diseases

Lan

et al. 2022

Sig Transduct Target Ther

219

View full text Add to dashboard Cite

As an evolutionarily conserved signalling network, the Hippo pathway plays a crucial role in the regulation of numerous biological processes. Thus, substantial efforts have been made to understand the upstream signals that influence the activity of the Hippo pathway, as well as its physiological functions, such as cell proliferation and differentiation, organ growth, embryogenesis, and tissue regeneration/wound healing. However, dysregulation of the Hippo pathway can cause a variety of diseases, including cancer, eye diseases, cardiac diseases, pulmonary diseases, renal diseases, hepatic diseases, and immune dysfunction. Therefore, therapeutic strategies that target dysregulated Hippo components might be promising approaches for the treatment of a wide spectrum of diseases. Here, we review the key components and upstream signals of the Hippo pathway, as well as the critical physiological functions controlled by the Hippo pathway. Additionally, diseases associated with alterations in the Hippo pathway and potential therapies targeting Hippo components will be discussed.

show abstract

Section: Key Components Of the Hippo Pathwaymentioning

confidence: 99%

The Hippo signalling pathway and its implications in human health and diseases

Lan

et al. 2022

Sig Transduct Target Ther

219

View full text Add to dashboard Cite

show abstract

“…GPCR inhibitors have also been describe to inhibit YAP/TAZ-TEAD indirectly ( Cunningham and Hansen, 2022 ). For instance, YM-254890, a specific G(α)q/11 inhibitor that indirectly inhibits YAP/TAZ ( Zindel et al, 2021 ), inhibited IH in a mouse model of vascular injury ( Kawasaki et al, 2005 ). However, YM-254890 also reduced systemic blood pressure and no further investigations were made in the context of IH ( Kawasaki et al, 2005 ).…”

Section: Treatment Of Intimal Hyperplasiamentioning

confidence: 99%

Vascular smooth muscle cells in intimal hyperplasia, an update

2023

View full text Add to dashboard Cite

Arterial occlusive disease is the leading cause of death in Western countries. Core contemporary therapies for this disease include angioplasties, stents, endarterectomies and bypass surgery. However, these treatments suffer from high failure rates due to re-occlusive vascular wall adaptations and restenosis. Restenosis following vascular surgery is largely due to intimal hyperplasia. Intimal hyperplasia develops in response to vessel injury, leading to inflammation, vascular smooth muscle cells dedifferentiation, migration, proliferation and secretion of extra-cellular matrix into the vessel’s innermost layer or intima. In this review, we describe the current state of knowledge on the origin and mechanisms underlying the dysregulated proliferation of vascular smooth muscle cells in intimal hyperplasia, and we present the new avenues of research targeting VSMC phenotype and proliferation.

show abstract

“…It is well established that Hippo-YAP pathway is emerging as important player in various types of cancers [27]. For example, in prostate cancer, inhibition of the Hippo-YAP pathway is su cient to activate apoptosis [28].…”

Section: Discussionmentioning

confidence: 99%

Gallic acid enhances the antitumor activity of Icotinib hydrochloride in non-small cell lung cancer via of Hippo-YAP signaling pathway in vitro and in vivo

Wang

Guo

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Icotinib hydrochloride (IH) is a small molecular TKI independently developed in China. As the first-line anti-tumor agent, is widely used for treatment of non-small cell lung cancer (NSCLC). Gallic acid (GA), a natural plant extract, is reported that it has a variety of pharmacological and biological properties. GA is a active natural phenolic extracted from Tannins that has been shown to exhibit anticancer activities on various types of tumors. Here, we reported that GA was capable of sensitizing A549/PC9 cells to IH by enhancing apoptosis. Mechanistic analyses indicated that IH-induced caspase-3-dependent apoptosis was elevated in the presence of GA through activating extracellular signal-regulated Hippo-YAP pathway. Furthermore, GA also promoted IH-induced cytotoxic, downregulated expression of p-YAP and caspase-3. In vivo, the co-treatment of IH and GA notably reduced the tumor size when compared with IH treatment alone. Notably, GA significantly reduced the toxicity generated by IH in tumor-bearing mice. This study identifies the unique role of GA enhance IH sensitivity through apoptosis, and suggests that combined IH and GA might be a novel therapeutic strategy for patients with NSCLC.

show abstract

G protein‐coupled receptors can control the Hippo/YAP pathway through Gq signaling

Cited by 19 publications

References 67 publications

The Hippo signalling pathway and its implications in human health and diseases

The Hippo signalling pathway and its implications in human health and diseases

Vascular smooth muscle cells in intimal hyperplasia, an update

Gallic acid enhances the antitumor activity of Icotinib hydrochloride in non-small cell lung cancer via of Hippo-YAP signaling pathway in vitro and in vivo

Contact Info

Product

Resources

About